DropGenie
DropGenie provides a platform that miniaturizes and parallelizes cell engineering reactions on patented chips, enabling high-efficiency delivery of mRNA, DNA, or proteins into any cell type at nanoliter volumes. The system achieves 100x miniaturization, 40x lower costs, and 100x faster results, making arrayed CRISPR screens feasible in precious immune samples. Its SBS-format, automation-ready design with direct cargo printing eliminates pipetting steps for streamlined workflows.
- Biotechnology
- Drug Discovery & Therapeutics
- Hardware
Funding
Raised to date
$10MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 2 rounds
AQBTC+2$5M · Seed Extension
Announced Oct 2026
Disclosed cumulative: $10M
Founders
Founder details are not available yet.
Product
Problem
Conventional cell engineering and CRISPR screening workflows require large sample volumes and expensive reagents, making arrayed screens impractical for precious or limited patient samples. Researchers face high costs, slow turnaround times, and significant cell stress, limiting the depth and scale of genomic discovery and personalized medicine development.
Solution
DropGenie offers a platform that miniaturizes and parallelizes cell engineering reactions on patented chips, delivering editing reagents into any cell type at nanoliter volumes. The system uses a proprietary electrode configuration to intelligently tune electrical parameters, enabling high-efficiency delivery of mRNA, DNA, or proteins with minimal cell stress. This approach supports arrayed CRISPR screens in scarce immune cells, achieving high-efficiency knockout with dramatically reduced cell input. The platform is SBS-format and automation-ready, allowing direct cargo printing and skip pipetting, which accelerates workflows from months to days and reduces costs by up to 40x.
Target Audience
Primary users are researchers in functional genomics and cell & gene therapy development, including those conducting arrayed CRISPR screens, TCR discovery, and CAR-immune cell engineering, particularly in settings with limited patient sample availability.
Features
- 100x miniaturization of reactions, enabling work with scarce or precious samples
- 40x lower cost through reduced reagent and labor consumption
- 100x faster results, delivering outcomes in days rather than weeks or months
- Cell-friendly delivery with high efficiency and minimal cell stress
- Compatible with any cargo (mRNA, DNA, proteins) and any cell type
- Direct cargo printing onto the chip, eliminating pipetting steps
- Adaptive tuning of electrical parameters for each condition
- Modular, SBS-format, and automation-ready design with no pumps or oils